People with epilepsy (PWE) are reported to have a lower quality of life (QOL). QOL among PWE were primarily observed through cross-sectional studies, and there is little information about the progression of QOL among PWE over the years. This study aimed to investigate the changes in QOL among PWE at a tertiary referral centre. A retrospective observational study was conducted among PWE from the Neurology clinic at the University Malaya Medical Centre. Data were extracted from the Quality of Life in Epilepsy Inventory (QOLIE-31) database for 2016, 2017, and 2020. A total of 88 subjects were included in Cohort 1 (2016 vs. 2017) and Cohort 2 (2017 vs. 2020), respectively. There was a significant improvement in mean scores of QOLIE-31 in Cohort 1 (57.7±12.2 vs. 63.2±14.2; p<0.001), in terms of seizure worry, emotional well-being, cognitive functioning, medication effects and social function (p<0.05, respectively). However, significant deterioration was observed in Cohort 2 (67.1±15.6 vs. 63.1±14.9; p=0.008), in terms of seizure worry and cognitive functioning (p<0.05, respectively). Based on the calculated Jacobson Reliable Change Index (RCI) for the QOLIE-31 score, 28.4% from Cohort 2 experienced deterioration of QOL as compared to those from Cohort 1 (8%) (p<0.001), which was most likely attributed to the COVID-19 pandemic. This study provides insights into the change of QOL among PWE in Malaysia over time, encompassing the COVID-19 pandemic period.
据报道，癫痫患者的生活质量（QOL）较低。人们主要通过横断面研究来观察癫痫患者的生活质量，而有关癫痫患者的生活质量随时间推移发生变化的信息却很少。本研究旨在调查一家三级转诊中心的残疾人生活质量的变化。研究人员对马来亚大学医疗中心神经病学诊所的残疾人进行了一项回顾性观察研究。研究人员从癫痫生活质量调查问卷（QOLIE-31）数据库中提取了2016年、2017年和2020年的数据。共有88名受试者分别被纳入队列1（2016年与2017年）和队列2（2017年与2020年）。队列1的QOLIE-31平均得分有明显改善（57.7±12.2 vs. 63.2±14.2；p<0.001），在癫痫发作担忧、情绪健康、认知功能、用药效果和社会功能方面（分别p<0.05）。然而，在组群 2 中，癫痫发作担忧和认知功能方面（分别为 67.1±15.6 vs. 63.1±14.9；p=0.008）出现了明显的恶化（p<0.05）。根据计算得出的 QOLIE-31 评分的雅各布森可靠变化指数 (RCI)，28.4% 的队列 2 患者比队列 1 患者（8%）的 QOL 出现恶化（p<0.001），这很可能是 COVID-19 大流行造成的。这项研究有助于深入了解马来西亚残疾人的 QOL 随 COVID-19 大流行期间的变化情况。
{"title":"Comparative retrospective analysis: exploring the quality of life of people with epilepsy in two cohorts","authors":"H. Yow, Kheng-Seang Lim, Melpreet Kuar Bhatt, Si-Lei Fong, Christine Audrey","doi":"10.31117/neuroscirn.v7i1.310","DOIUrl":"https://doi.org/10.31117/neuroscirn.v7i1.310","url":null,"abstract":"People with epilepsy (PWE) are reported to have a lower quality of life (QOL). QOL among PWE were primarily observed through cross-sectional studies, and there is little information about the progression of QOL among PWE over the years. This study aimed to investigate the changes in QOL among PWE at a tertiary referral centre. A retrospective observational study was conducted among PWE from the Neurology clinic at the University Malaya Medical Centre. Data were extracted from the Quality of Life in Epilepsy Inventory (QOLIE-31) database for 2016, 2017, and 2020. A total of 88 subjects were included in Cohort 1 (2016 vs. 2017) and Cohort 2 (2017 vs. 2020), respectively. There was a significant improvement in mean scores of QOLIE-31 in Cohort 1 (57.7±12.2 vs. 63.2±14.2; p<0.001), in terms of seizure worry, emotional well-being, cognitive functioning, medication effects and social function (p<0.05, respectively). However, significant deterioration was observed in Cohort 2 (67.1±15.6 vs. 63.1±14.9; p=0.008), in terms of seizure worry and cognitive functioning (p<0.05, respectively). Based on the calculated Jacobson Reliable Change Index (RCI) for the QOLIE-31 score, 28.4% from Cohort 2 experienced deterioration of QOL as compared to those from Cohort 1 (8%) (p<0.001), which was most likely attributed to the COVID-19 pandemic. This study provides insights into the change of QOL among PWE in Malaysia over time, encompassing the COVID-19 pandemic period.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140383639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-25DOI: 10.31117/neuroscirn.v7i1.284
N. H. Mohad Azmi, S. Suppiah, Nur Shahidatul Nabila Ibrahim, I. Buhari, Vengkhata Priya Seriramulu, M. Mohamad, T. Karuppiah, Nur Farhayu Omar, N. Ibrahim, R. M. Razali, N. H. Harrun, H. Sallehuddin, N. Syed Nasser, Umar Ahmad
The default mode network (DMN) is a large neural network that has a significant correlation with Alzheimer's disease (AD). Grey matter volume (GMV) and functional connectivity (FC) involving the regions of the DMN have been noted to differ significantly between AD and healthy older adults. Nevertheless, there is a paucity of data on the structural and functional changes in the DMN of AD patients in Malaysia. We conducted a cross-sectional study in Klang Valley, Malaysia, to evaluate AD subjects compared to healthy controls (HC) using a resting-state functional MRI (rs-fMRI) experiment. We recruited 22 subjects (AD=11, HC=11) and conducted neuropsychological tests such as the Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), and Clinical Dementia Rating (CDR). The subjects then underwent rs-fMRI scans, and subsequently, we quantitatively analysed the GMV by Voxel based Morphometry (VBM) using the structural data. We also utilised the CONN toolbox on Statistical Parametric Mapping (SPM) software to evaluate the FC and activation of the nodes of the DMN. In comparison with the HC group, the AD group demonstrated a reduction in GMV in the right and left inferior temporal gyrus, left superior frontal gyrus, right superior frontal gyrus medial segment, right gyrus rectus, right temporal lobe, left putamen, and right precuneus. Moreover, there was a significant decrease in the FC of the nodes of the DMN noted on rs-fMRI (cluster-size corrected p<0.05). In particular, the precuneus and anterior cingulate cortex had decreased FC in AD compared to HC. Hence, structural and resting-state fMRI can detect distinct imaging biomarkers of AD based on GMV and DMN functional connectivity profiles. This tool can be used as a non-invasive tool for improving the feature detection and diagnosis of AD in the Malaysian population.
{"title":"Default mode network perturbations in Alzheimer's disease: an fMRI study in Klang Valley, Malaysia","authors":"N. H. Mohad Azmi, S. Suppiah, Nur Shahidatul Nabila Ibrahim, I. Buhari, Vengkhata Priya Seriramulu, M. Mohamad, T. Karuppiah, Nur Farhayu Omar, N. Ibrahim, R. M. Razali, N. H. Harrun, H. Sallehuddin, N. Syed Nasser, Umar Ahmad","doi":"10.31117/neuroscirn.v7i1.284","DOIUrl":"https://doi.org/10.31117/neuroscirn.v7i1.284","url":null,"abstract":"The default mode network (DMN) is a large neural network that has a significant correlation with Alzheimer's disease (AD). Grey matter volume (GMV) and functional connectivity (FC) involving the regions of the DMN have been noted to differ significantly between AD and healthy older adults. Nevertheless, there is a paucity of data on the structural and functional changes in the DMN of AD patients in Malaysia. We conducted a cross-sectional study in Klang Valley, Malaysia, to evaluate AD subjects compared to healthy controls (HC) using a resting-state functional MRI (rs-fMRI) experiment. We recruited 22 subjects (AD=11, HC=11) and conducted neuropsychological tests such as the Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), and Clinical Dementia Rating (CDR). The subjects then underwent rs-fMRI scans, and subsequently, we quantitatively analysed the GMV by Voxel based Morphometry (VBM) using the structural data. We also utilised the CONN toolbox on Statistical Parametric Mapping (SPM) software to evaluate the FC and activation of the nodes of the DMN. In comparison with the HC group, the AD group demonstrated a reduction in GMV in the right and left inferior temporal gyrus, left superior frontal gyrus, right superior frontal gyrus medial segment, right gyrus rectus, right temporal lobe, left putamen, and right precuneus. Moreover, there was a significant decrease in the FC of the nodes of the DMN noted on rs-fMRI (cluster-size corrected p<0.05). In particular, the precuneus and anterior cingulate cortex had decreased FC in AD compared to HC. Hence, structural and resting-state fMRI can detect distinct imaging biomarkers of AD based on GMV and DMN functional connectivity profiles. This tool can be used as a non-invasive tool for improving the feature detection and diagnosis of AD in the Malaysian population.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140383796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-23DOI: 10.31117/neuroscirn.v7i1.302
S. Gultekin, I. Albayrak, Y. Diler, Ayse Destina Yalcin, B. Arslan
Alzheimer's disease (AD), which is a neurodegenerative disease, cannot be noticed until severe symptoms are observed. This poses a global challenge as the average human lifespan increases, making it a concern for the entire world population. Early diagnosis can play a crucial role in slowing the progression of the disease, thereby enhancing the quality of life for both the patient and their relatives. AD has been linked to alterations in mRNA expressions. The objective of the presented study was to determine whether there were significant differences in gene expression in blood plasma between Alzheimer's patients and healthy controls. MAPT, APP, Tubb3, TrkB, and CDC42 genes were selected as target genes due to their potential associations with AD. To analyse mRNA expression levels in the control group and AD patients, the real-time PCR (qPCR) method was performed. The findings indicate that MAPT, APP, Tubb3, and CDC42 genes' expression levels were significantly downregulated by 1.09, 1.08, 1.09, and 1.14 times, respectively (p<0.05) in AD patients. Although the TrkB gene expression appeared to be downregulated by 1.03 times in the AD group, it is not statistically different. Given the molecular associations between the pathways of the target genes and AD, changes in the expression of these genes may contribute to the pathogenesis of AD. They may represent potential biomarkers for early diagnosis.
阿尔茨海默病（AD）是一种神经退行性疾病，直到出现严重症状时才会被发现。随着人类平均寿命的延长，这种疾病已成为一个全球性挑战，令全世界的人们都感到担忧。早期诊断可在减缓疾病进展方面发挥关键作用，从而提高患者及其亲属的生活质量。注意力缺失症与 mRNA 表达的改变有关。本研究的目的是确定阿尔茨海默病患者和健康对照者血浆中的基因表达是否存在显著差异。由于 MAPT、APP、Tubb3、TrkB 和 CDC42 基因可能与老年痴呆症有关，因此被选为目标基因。为了分析对照组和 AD 患者的 mRNA 表达水平，研究人员采用了实时 PCR（qPCR）方法。结果表明，在AD患者中，MAPT、APP、Tubb3和CDC42基因的表达水平分别显著下调了1.09倍、1.08倍、1.09倍和1.14倍（P<0.05）。虽然TrkB基因的表达在AD组中似乎下调了1.03倍，但没有统计学差异。鉴于目标基因的通路与 AD 之间的分子关联，这些基因表达的变化可能有助于 AD 的发病机制。它们可能是早期诊断的潜在生物标志物。
{"title":"Gene expression analysis in plasma of patients with Alzheimer's disease","authors":"S. Gultekin, I. Albayrak, Y. Diler, Ayse Destina Yalcin, B. Arslan","doi":"10.31117/neuroscirn.v7i1.302","DOIUrl":"https://doi.org/10.31117/neuroscirn.v7i1.302","url":null,"abstract":"Alzheimer's disease (AD), which is a neurodegenerative disease, cannot be noticed until severe symptoms are observed. This poses a global challenge as the average human lifespan increases, making it a concern for the entire world population. Early diagnosis can play a crucial role in slowing the progression of the disease, thereby enhancing the quality of life for both the patient and their relatives. AD has been linked to alterations in mRNA expressions. The objective of the presented study was to determine whether there were significant differences in gene expression in blood plasma between Alzheimer's patients and healthy controls. MAPT, APP, Tubb3, TrkB, and CDC42 genes were selected as target genes due to their potential associations with AD. To analyse mRNA expression levels in the control group and AD patients, the real-time PCR (qPCR) method was performed. The findings indicate that MAPT, APP, Tubb3, and CDC42 genes' expression levels were significantly downregulated by 1.09, 1.08, 1.09, and 1.14 times, respectively (p<0.05) in AD patients. Although the TrkB gene expression appeared to be downregulated by 1.03 times in the AD group, it is not statistically different. Given the molecular associations between the pathways of the target genes and AD, changes in the expression of these genes may contribute to the pathogenesis of AD. They may represent potential biomarkers for early diagnosis.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140386773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Parkinson’s disease (PD) is classified as one type of neurodegenerative disorder. Movement disorder, which includes resting tremors and slowness of movement, is a common clinical symptom in PD patients. Neuroinflammation is one of the most important processes involved in the pathogenesis of PD. An inflammatory response in the brain can induce neuronal cell death. Microglia, a type of immune cell, plays a crucial role in neuroinflammation. In this review, we discussed the information on microglia-activated neuroinflammation, its relationship with PD, and therapeutic approaches for neuroinflammation in PD. Under normal conditions, microglia in their inactive state (M0) act as surveillance agents in the brain to investigate potential invasions. They regulate neuron production, remodel synapses, and secrete growth factors to protect the neurons. Under pathological conditions, the M0 transforms into active phenotypes, dividing into pro-inflammatory (M1) and anti-inflammatory (M2) microglia. The M1 and M2 microglia exhibit opposite functions, where M1 microglia promote pro-inflammatory responses, and M2 microglia promote anti-inflammatory responses. This dichotomy of functions is essential for maintaining a healthy level of inflammation in the brain. Presently, multiple therapeutic strategies are available for PD, encompassing anti-inflammatory drugs, neuroprotective compounds, antioxidants, nanoparticles targeting neuroinflammation, stem cell interventions, lifestyle adjustments, and microglia-focused treatments. These treatments improve patients' movement, allowing them to have lifestyles like others, consequently benefiting their mental and emotional well-being. Preventing microglia from polarising into the M1 phenotype and promoting their polarisation into the M2 phenotype could be a challenging and promising approach for treating PD.
{"title":"Neuroinflammation-induced neurodegeneration and associated microglia activation in Parkinson’s disease: a novel neurotherapeutic avenue","authors":"Panlekha Rungruang, Veerawat Sansri, Morakot Sroyraya","doi":"10.31117/neuroscirn.v7i1.271","DOIUrl":"https://doi.org/10.31117/neuroscirn.v7i1.271","url":null,"abstract":"Parkinson’s disease (PD) is classified as one type of neurodegenerative disorder. Movement disorder, which includes resting tremors and slowness of movement, is a common clinical symptom in PD patients. Neuroinflammation is one of the most important processes involved in the pathogenesis of PD. An inflammatory response in the brain can induce neuronal cell death. Microglia, a type of immune cell, plays a crucial role in neuroinflammation. In this review, we discussed the information on microglia-activated neuroinflammation, its relationship with PD, and therapeutic approaches for neuroinflammation in PD. Under normal conditions, microglia in their inactive state (M0) act as surveillance agents in the brain to investigate potential invasions. They regulate neuron production, remodel synapses, and secrete growth factors to protect the neurons. Under pathological conditions, the M0 transforms into active phenotypes, dividing into pro-inflammatory (M1) and anti-inflammatory (M2) microglia. The M1 and M2 microglia exhibit opposite functions, where M1 microglia promote pro-inflammatory responses, and M2 microglia promote anti-inflammatory responses. This dichotomy of functions is essential for maintaining a healthy level of inflammation in the brain. Presently, multiple therapeutic strategies are available for PD, encompassing anti-inflammatory drugs, neuroprotective compounds, antioxidants, nanoparticles targeting neuroinflammation, stem cell interventions, lifestyle adjustments, and microglia-focused treatments. These treatments improve patients' movement, allowing them to have lifestyles like others, consequently benefiting their mental and emotional well-being. Preventing microglia from polarising into the M1 phenotype and promoting their polarisation into the M2 phenotype could be a challenging and promising approach for treating PD.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140235243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This review paper explores the history, development, current state, and future prospects of psychological science in Mongolia. The establishment of the first department of pedagogical psychology in 1954 and the publication of the first Mongolian psychology textbook in 1960 marked the initial steps in the field's development. Dr. Sanjjav Damdinjav's pioneering PhD in 1966 and subsequent international representation paved the way for further growth. Currently, most Mongolian psychologists work across both public and private sectors. Education, healthcare, and justice/military services are the key employer groups in the public sector. Promising research has emerged in recent years, focusing on child and youth development, social support and well-being, psychological factors and financial credit risk, and tool adaptation for psychological assessment. Despite these advancements, significant challenges remain. These include a need for nationally licensed graduate programs, limited research funding, an outdated academic system, political interference in public university governance, a shortage of specialised personnel, and high research infrastructure costs. The most pressing issue is the need for graduate programs and corresponding job opportunities for major specialities like clinical, cognitive, and developmental psychology. Potential solutions include introducing graduate programs in key specialities, establishing licensure regulations, addressing systemic gaps, and increasing financial support for research institutions and universities. These steps would lay a strong foundation for the field, fostering its sustained growth and enabling meaningful contributions to Mongolian development.
{"title":"Psychological science in Mongolia: Its history, development, and future prospects","authors":"Binderiya Bayanmunkh, Batsukh Shairii, Buyantungalag Battulga, Tsolmon Jadamba, Battuvshin Lkhagvasuren, Bayarmaa Tsend","doi":"10.31117/neuroscirn.v7i1.242","DOIUrl":"https://doi.org/10.31117/neuroscirn.v7i1.242","url":null,"abstract":"This review paper explores the history, development, current state, and future prospects of psychological science in Mongolia. The establishment of the first department of pedagogical psychology in 1954 and the publication of the first Mongolian psychology textbook in 1960 marked the initial steps in the field's development. Dr. Sanjjav Damdinjav's pioneering PhD in 1966 and subsequent international representation paved the way for further growth. Currently, most Mongolian psychologists work across both public and private sectors. Education, healthcare, and justice/military services are the key employer groups in the public sector. Promising research has emerged in recent years, focusing on child and youth development, social support and well-being, psychological factors and financial credit risk, and tool adaptation for psychological assessment. Despite these advancements, significant challenges remain. These include a need for nationally licensed graduate programs, limited research funding, an outdated academic system, political interference in public university governance, a shortage of specialised personnel, and high research infrastructure costs. The most pressing issue is the need for graduate programs and corresponding job opportunities for major specialities like clinical, cognitive, and developmental psychology. Potential solutions include introducing graduate programs in key specialities, establishing licensure regulations, addressing systemic gaps, and increasing financial support for research institutions and universities. These steps would lay a strong foundation for the field, fostering its sustained growth and enabling meaningful contributions to Mongolian development.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140234613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The application of neurofeedback is gaining increasing interest among neuroscientists as a potential neurorehabilitation approach in cases of various neuro-related functional abnormalities. Discovering the current state of research and identifying gaps in the field of neurofeedback is an essential step in planning and mapping out future research efforts. This bibliometric analysis paper aims to identify the publications and research in neurofeedback from 2000 to 2022. A comprehensive Scopus database search was conducted using the keyword "neurofeedback" and relevant publications from 2000 to 2022 were retrieved. Bibliometric analyses were performed using the Harzing's Publish or Perish and VOSviewer software programmes. The number of retrieved documents was 1835. The number of publications has shown a steadily increasing trend since 2000, with a prominent spike in publications in 2014–2015, indicating a sudden interest in neurofeedback. Among the retrieved documents, 50.3% were related to neuroscience, 23.7% related to medicine, and 13.1% related to psychology. The main contributors to this research come from the United States (24.7%), Germany (13.7%), the United Kingdom (9.4%), and Switzerland (4.9%). Based on the network visualisation of author keywords, the most frequently occurring keywords were neurofeedback, real-time functional magnetic resonance imaging (fMRI), brain-computer interface (BCI), neuromodulation, and neurofeedback training. This bibliometric analysis presents the current status, knowledge base, and future neurofeedback study directions. These findings will benefit future researchers interested in applying neurofeedback as a potential neurorehabilitation approach for a wider population.
{"title":"Bibliometric analysis of neurofeedback research from 2000 to 2022","authors":"Siti Atiyah Ali, Mazira Mohamad Ghazali, Nurfaizatul Aisyah Ab Aziz, Humaira Nisar","doi":"10.31117/neuroscirn.v7i1.265","DOIUrl":"https://doi.org/10.31117/neuroscirn.v7i1.265","url":null,"abstract":"The application of neurofeedback is gaining increasing interest among neuroscientists as a potential neurorehabilitation approach in cases of various neuro-related functional abnormalities. Discovering the current state of research and identifying gaps in the field of neurofeedback is an essential step in planning and mapping out future research efforts. This bibliometric analysis paper aims to identify the publications and research in neurofeedback from 2000 to 2022. A comprehensive Scopus database search was conducted using the keyword \"neurofeedback\" and relevant publications from 2000 to 2022 were retrieved. Bibliometric analyses were performed using the Harzing's Publish or Perish and VOSviewer software programmes. The number of retrieved documents was 1835. The number of publications has shown a steadily increasing trend since 2000, with a prominent spike in publications in 2014–2015, indicating a sudden interest in neurofeedback. Among the retrieved documents, 50.3% were related to neuroscience, 23.7% related to medicine, and 13.1% related to psychology. The main contributors to this research come from the United States (24.7%), Germany (13.7%), the United Kingdom (9.4%), and Switzerland (4.9%). Based on the network visualisation of author keywords, the most frequently occurring keywords were neurofeedback, real-time functional magnetic resonance imaging (fMRI), brain-computer interface (BCI), neuromodulation, and neurofeedback training. This bibliometric analysis presents the current status, knowledge base, and future neurofeedback study directions. These findings will benefit future researchers interested in applying neurofeedback as a potential neurorehabilitation approach for a wider population.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140236583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-31DOI: 10.31117/neuroscirn.v7i1.225
Dhivya P Sundaram, Swathy Govindaswamy, Sobiya Mathiazhagan, Jayalakshmi Venugopal
Alzheimer's disease refers to a pathological topography accompanied by the loss of neurons in the brain regions including entorhinal cortex and hippocampus, resulting in memory impairment, cognitive dysfunction, behavioural problems, and difficulties in activities of daily living that ultimately lead to mortality. This disease typically affects the elderly population. Even if the underlying pathophysiological mechanisms are unclear, Alzheimer's disease is unquestionably associated with dysfunction in the cholinergic system, resulting in a decreased level of acetylcholine in specific brain regions, including the entorhinal cortex and hippocampus. Although significant progress has been made in understanding the molecular and cellular causes of Alzheimer's disease, there is presently no medication available to reduce or stop the loss of brain cells. As the number of individuals with Alzheimer's disease continues to rise, there is a pressing need to develop ways for early diagnosis and offer viable treatments to avert a public health crisis. In recent years, nanoparticles have been seriously studied as a diagnostic and therapeutic tool for Alzheimer's disease. Here, we discuss the recent growth in nanoparticles for Alzheimer's disease diagnosis and treatment.
{"title":"Role of nanotechnology in therapeutics and diagnosis of Alzheimer’s disease","authors":"Dhivya P Sundaram, Swathy Govindaswamy, Sobiya Mathiazhagan, Jayalakshmi Venugopal","doi":"10.31117/neuroscirn.v7i1.225","DOIUrl":"https://doi.org/10.31117/neuroscirn.v7i1.225","url":null,"abstract":"Alzheimer's disease refers to a pathological topography accompanied by the loss of neurons in the brain regions including entorhinal cortex and hippocampus, resulting in memory impairment, cognitive dysfunction, behavioural problems, and difficulties in activities of daily living that ultimately lead to mortality. This disease typically affects the elderly population. Even if the underlying pathophysiological mechanisms are unclear, Alzheimer's disease is unquestionably associated with dysfunction in the cholinergic system, resulting in a decreased level of acetylcholine in specific brain regions, including the entorhinal cortex and hippocampus. Although significant progress has been made in understanding the molecular and cellular causes of Alzheimer's disease, there is presently no medication available to reduce or stop the loss of brain cells. As the number of individuals with Alzheimer's disease continues to rise, there is a pressing need to develop ways for early diagnosis and offer viable treatments to avert a public health crisis. In recent years, nanoparticles have been seriously studied as a diagnostic and therapeutic tool for Alzheimer's disease. Here, we discuss the recent growth in nanoparticles for Alzheimer's disease diagnosis and treatment.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140477957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-31DOI: 10.31117/neuroscirn.v6i4.262
Ainon Zahariah Samsudin, K. Ramasamy, S. Lim, A. Chin, Maw Pin Tan, S. Kamaruzzaman, Baharudin Ibrahim, Abu Bakar Abdul Majeed
This study uncovered differential gene expression in blood to distinguish subjects with probable Alzheimer’s disease (AD) from normal elderly participants (non-demented controls, NDC). The participants were recruited via training (Phase 1) and validation cohorts (Phase 2). The changes of gene expression in blood samples from the training cohort (92 AD vs 92 NDC) were assessed using the microarray technology. The Partial Least Square Discrimination Analysis (PLSDA) was then used to develop a disease classifier algorithm (accuracy = 88.3%). Six differentially expressed genes were validated through RT-qPCR using blood samples from the validation cohort [(25 AD, 25 NDC, 12 mild cognitive impairment (MCI) and 12 vascular dementia (VaD) subjects] . The PLSDA model indicated a good separation between AD and NDC [area under the receiver operating characteristic curve (ROC AUC) = 0.88]. ABCA9, CNOT8, SESN1, UCP3, MAP2K1 and DDIT4 were found to be differentially expressed between the two groups. Validation of the panel of six genes gave an overall accuracy of 82.0% (AUC=0.86). The ABCA9 mRNA level, which was significantly (p < 0.05) lower in the AD group, correctly classified 90.9% of all subjects (AUC=0.94). This group of genes may be responsible for dysregulation of pathways related to inflammation, mitochondrial dysfunction, oxidative injury, DNA damage, apoptosis and lipid metabolism. The disease classifier algorithm discriminated probable AD from MCI and VaD at specificity of 83.3% and 75.0%, respectively. These findings warrant further validation of potential blood-based biomarkers in larger samples of clinical AD.
{"title":"Differential gene expression of blood-based ABCA9, CNOT8, SESN1, UCP3, MAP2K1 and DDIT4 in Alzheimer’s disease","authors":"Ainon Zahariah Samsudin, K. Ramasamy, S. Lim, A. Chin, Maw Pin Tan, S. Kamaruzzaman, Baharudin Ibrahim, Abu Bakar Abdul Majeed","doi":"10.31117/neuroscirn.v6i4.262","DOIUrl":"https://doi.org/10.31117/neuroscirn.v6i4.262","url":null,"abstract":"This study uncovered differential gene expression in blood to distinguish subjects with probable Alzheimer’s disease (AD) from normal elderly participants (non-demented controls, NDC). The participants were recruited via training (Phase 1) and validation cohorts (Phase 2). The changes of gene expression in blood samples from the training cohort (92 AD vs 92 NDC) were assessed using the microarray technology. The Partial Least Square Discrimination Analysis (PLSDA) was then used to develop a disease classifier algorithm (accuracy = 88.3%). Six differentially expressed genes were validated through RT-qPCR using blood samples from the validation cohort [(25 AD, 25 NDC, 12 mild cognitive impairment (MCI) and 12 vascular dementia (VaD) subjects] . The PLSDA model indicated a good separation between AD and NDC [area under the receiver operating characteristic curve (ROC AUC) = 0.88]. ABCA9, CNOT8, SESN1, UCP3, MAP2K1 and DDIT4 were found to be differentially expressed between the two groups. Validation of the panel of six genes gave an overall accuracy of 82.0% (AUC=0.86). The ABCA9 mRNA level, which was significantly (p < 0.05) lower in the AD group, correctly classified 90.9% of all subjects (AUC=0.94). This group of genes may be responsible for dysregulation of pathways related to inflammation, mitochondrial dysfunction, oxidative injury, DNA damage, apoptosis and lipid metabolism. The disease classifier algorithm discriminated probable AD from MCI and VaD at specificity of 83.3% and 75.0%, respectively. These findings warrant further validation of potential blood-based biomarkers in larger samples of clinical AD.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139132245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-23DOI: 10.31117/neuroscirn.v6i4.248
Nur Shahidatul Nabila Ibrahim, S. Suppiah, B. Ibrahim, N. H. Mohad Azmi, V. P. Seriramulu, M. Mohamad, M. Hanafi, H. Mohammad Sallehuddin, R. M. Razali, N. H. Harrun
Dementia is a spectrum of diseases characterised by a progressive and irreversible decline in cognitive function. Appropriate tools and references are essential for evaluating individuals' cognitive levels, especially hippocampal volume, as it is the commonly used biomarker in detecting Alzheimer's disease (AD). It is important to note that while there is no cure for dementia, early intervention and support can greatly improve the lives of those affected. Our ongoing AD research is being conducted to develop new treatments and improve our understanding of the disease by using voxel-based morphometry (VBM) to compare sensitivity and specificity with the HippoDeep toolbox. We validated AD's hippocampal volume compared to age-matched healthy controls (HC) based on the HippoDeep Model by comparing it with VBM as the reference standard. Significant differences between hippocampal volume in AD and HC have been detected using VBM and HippoDeep analysis.
痴呆症是以认知功能进行性和不可逆下降为特征的一系列疾病。适当的工具和参考资料对于评估个人的认知水平至关重要，尤其是海马体积，因为它是检测阿尔茨海默病（AD）的常用生物标志物。值得注意的是，虽然痴呆症无法治愈，但早期干预和支持可以大大改善患者的生活。我们正在进行的阿尔茨海默病研究旨在开发新的治疗方法，并通过使用体素形态计量学（VBM）来比较 HippoDeep 工具箱的灵敏度和特异性，从而提高我们对该疾病的认识。我们以HippoDeep模型为基础，通过与作为参考标准的VBM进行比较，验证了与年龄匹配的健康对照组（HC）相比，AD的海马体积。通过 VBM 和 HippoDeep 分析，我们发现 AD 和 HC 的海马体积存在显著差异。
{"title":"Comparison of deep learning convolutional neural networks method with conventional volume-based morphometry measurement of hippocampal volume in Alzheimer's disease","authors":"Nur Shahidatul Nabila Ibrahim, S. Suppiah, B. Ibrahim, N. H. Mohad Azmi, V. P. Seriramulu, M. Mohamad, M. Hanafi, H. Mohammad Sallehuddin, R. M. Razali, N. H. Harrun","doi":"10.31117/neuroscirn.v6i4.248","DOIUrl":"https://doi.org/10.31117/neuroscirn.v6i4.248","url":null,"abstract":"Dementia is a spectrum of diseases characterised by a progressive and irreversible decline in cognitive function. Appropriate tools and references are essential for evaluating individuals' cognitive levels, especially hippocampal volume, as it is the commonly used biomarker in detecting Alzheimer's disease (AD). It is important to note that while there is no cure for dementia, early intervention and support can greatly improve the lives of those affected. Our ongoing AD research is being conducted to develop new treatments and improve our understanding of the disease by using voxel-based morphometry (VBM) to compare sensitivity and specificity with the HippoDeep toolbox. We validated AD's hippocampal volume compared to age-matched healthy controls (HC) based on the HippoDeep Model by comparing it with VBM as the reference standard. Significant differences between hippocampal volume in AD and HC have been detected using VBM and HippoDeep analysis.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139162151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-11DOI: 10.31117/neuroscirn.v6i4.276
A. Papadopoulos, Ioannis Vogindroukas, A. Tsapara, Louiza Voniati, D. Tafiadis, Panagiotis Plotas
As a neurodevelopmental condition, autism spectrum disorder (ASD) is characterised by pervasive social interaction and communication deficits. This review aimed to identify and synthesise the latest literature about the effectiveness of the Intensive Interaction approach in children with ASD. The review was conducted according to the PRISMA guidelines. The total number of children with ASD was 28, aged from 4 to 14 years old, with 27 males and only one female. The studies addressed intervention goals related to non-verbal and intentional communication, behavioural difficulties, joint attention, and parent-child interaction. The findings from the studies indicated that children with ASD had a positive outcome from the involvement in the Intensive Interaction approach. Regrettably, the constraints imposed by the methodology and design employed in the studies, coupled with the limited sample sizes (two of the studies consisted of a single case), preclude forming any definitive conclusions about the impacts of Intensive Interaction. However, the evidence is at least sufficient to support the assertions put forth by the authors. Despite the encouraging evidence of the effectiveness of the Intensive Interaction approach, multiple factors contribute as barriers to this issue, including the inherent challenges associated with conducting high-quality research that adheres to rigorous methodological standards.
{"title":"Intensive Interaction as an intervention approach in children with autism spectrum disorder: a systematic review","authors":"A. Papadopoulos, Ioannis Vogindroukas, A. Tsapara, Louiza Voniati, D. Tafiadis, Panagiotis Plotas","doi":"10.31117/neuroscirn.v6i4.276","DOIUrl":"https://doi.org/10.31117/neuroscirn.v6i4.276","url":null,"abstract":"As a neurodevelopmental condition, autism spectrum disorder (ASD) is characterised by pervasive social interaction and communication deficits. This review aimed to identify and synthesise the latest literature about the effectiveness of the Intensive Interaction approach in children with ASD. The review was conducted according to the PRISMA guidelines. The total number of children with ASD was 28, aged from 4 to 14 years old, with 27 males and only one female. The studies addressed intervention goals related to non-verbal and intentional communication, behavioural difficulties, joint attention, and parent-child interaction. The findings from the studies indicated that children with ASD had a positive outcome from the involvement in the Intensive Interaction approach. Regrettably, the constraints imposed by the methodology and design employed in the studies, coupled with the limited sample sizes (two of the studies consisted of a single case), preclude forming any definitive conclusions about the impacts of Intensive Interaction. However, the evidence is at least sufficient to support the assertions put forth by the authors. Despite the encouraging evidence of the effectiveness of the Intensive Interaction approach, multiple factors contribute as barriers to this issue, including the inherent challenges associated with conducting high-quality research that adheres to rigorous methodological standards.","PeriodicalId":36108,"journal":{"name":"Neuroscience Research Notes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139010495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：